Axsome Therapeutics Inc
Axsome Therapeutics Inc (AXSM) Straddle
AXSM straddle scan found 249 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 54.3%.
Read more
Trading a AXSM straddle lets you take a pure volatility position on Axsome Therapeutics Inc without committing to a direction. Axsome Therapeutics Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate AXSM straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on AXSM profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Axsome Therapeutics Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the AXSM straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia.
Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the AXSM straddle is the cleanest expression of that view. Our scanner prices every AXSM straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a AXSM straddle into a catalyst or short a AXSM straddle to harvest decay, the options straddle setups that matter are all in one place.
| Jan 21, 2028 | 380.00 | $192.70 | 485 | 63% | 54.3% | $572.70 | $187.30 | 0 |
| Jan 21, 2028 | 360.00 | $174.10 | 485 | 63% | 54.2% | $534.10 | $185.90 | 0 |
| Jan 21, 2028 | 370.00 | $183.55 | 485 | 63% | 54.2% | $553.55 | $186.45 | 0 |
| Jan 21, 2028 | 350.00 | $165.00 | 485 | 63% | 54.1% | $515.00 | $185.00 | 0 |
| Jan 21, 2028 | 340.00 | $156.25 | 485 | 63% | 53.9% | $496.25 | $183.75 | 0 |
| Nov 19, 2027 | 370.00 | $182.00 | 422 | 63% | 53.9% | $552.00 | $188.00 | 0 |
| Jan 21, 2028 | 330.00 | $147.75 | 485 | 63% | 53.7% | $477.75 | $182.25 | 0 |
| Nov 19, 2027 | 350.00 | $163.50 | 422 | 63% | 53.7% | $513.50 | $186.50 | 0 |
| Nov 19, 2027 | 360.00 | $173.00 | 422 | 63% | 53.6% | $533.00 | $187.00 | 0 |
| Nov 19, 2027 | 340.00 | $154.50 | 422 | 63% | 53.5% | $494.50 | $185.50 | 0 |
As of September 23, 2026
Find the right straddle before volatility moves
Track AXSM straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→